Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT

Core Viewpoint - Corcept Therapeutics Incorporated is facing a class action lawsuit for alleged violations of securities laws, specifically for making false and misleading statements regarding its product candidate, relacorilant, during the class period from October 31, 2024, to December 30, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that Corcept misled investors by stating that relacorilant was "approaching approval" despite receiving warnings from the FDA about insufficient clinical data [1]. - The deadline for shareholders to participate in the lawsuit is April 21, 2026 [1]. - The class action is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. Group 2: Company Background - Corcept Therapeutics is publicly traded on NASDAQ under the ticker symbol CORT [1]. - The company is accused of making materially misleading public statements throughout the class period, which could have significant implications for its stock value and investor trust [1].